United Laboratories flags profit drop on weaker bulk drug prices despite licensing boost

The United Laboratories International Holdings ( (HK:3933) ) just unveiled an announcement.

The United Laboratories International Holdings has warned that its 2025 profit is expected to fall to about RMB2 billion, down from roughly RMB2.66 billion a year earlier, based on unaudited management accounts. The decline is primarily attributed to sharp drops in market prices for intermediate products and bulk medicines, which cut segment profits by around RMB1.6 billion and RMB400 million, respectively, though a strong rise in finished products profit, including about RMB1.3 billion in license fee income from Novo Nordisk, partially offset the impact.

The announcement underscores the group’s growing reliance on higher-value finished products and licensing income to counter volatility in its upstream businesses. Investors are cautioned that the figures are preliminary and unaudited, and the final 2025 results may differ when the full annual report is released, adding an element of earnings uncertainty for shareholders and potential investors.

The most recent analyst rating on (HK:3933) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.

More about The United Laboratories International Holdings

The United Laboratories International Holdings is a Hong Kong-listed pharmaceutical group incorporated in the Cayman Islands. It operates across intermediate products, bulk medicine, and finished pharmaceutical products, with a notable revenue contribution from licensing arrangements such as its deal with Novo Nordisk A/S.

Average Trading Volume: 9,687,868

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$25.79B

Find detailed analytics on 3933 stock on TipRanks’ Stock Analysis page.